Therefore, quercetin may be used as a potential drug treating vascular-remodeling related PAH by inhibiting endothelial transdifferentiation possibly via modulating the expression and phosphorylation levels of Akt and Erk1/2 pathways. Here, AKT1 is linked to pulmonary arterial hypertension.